Cancer - Fore Biotherapeutics

A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients with Advanced, Unresectable Solid Tumors

Drug

FORE8394

Condition

Advanced Unresectable Solid Tumors with Activating BRAF Mutations